Antimicrobial Potential of Streptomyces spp. Isolated from the Rift Valley Regions of Ethiopia
Table 3
The antimicrobial activity (mm) of the isolates against bacterial pathogens during secondary screening.
S.No.
Test pathogens
Isolates code
Gram-negative bacteria
Gram-positive bacteria
Fungi
Ec
Kp
Pa
St1
St2
Sa
Se
A. niger
1
RVE002
19 ± 0.6i
12 ± 0.0de
16 ± 0.6g
15 ± 0.0fg
12 ± 0.6ef
22 ± 0.0g
19 ± 1.0k
22 ± 1.2j
2
RVE004
5 ± 0.0b
0 ± 0.0a
18 ± 1.2f
13 ± 1.2de
0 ± 0.0a
9 ± 1.0cd
8 ± 0.0bc
17 ± 0.6h
3
RVE029
0 ± 0.0a
10 ± 0.6cd
14 ± 0.0c
7 ± 0.0b
12 ± 0.6ef
17 ± 0.0f
24 ± 0.6l
16 ± 0.0h
4
RVE077
17 ± 0.0h
12 ± 0.6de
9 ± 0.0b
15 ± 0.6fg
18 ± 0.6h
14 ± 1.2e
0 ± 0.0a
9 ± 0.0ef
5
RVE116
15 ± 1.2g
14 ± 0.0f
16 ± 0.0de
6 ± 2. 3b
0 ± 0.0a
7 ± 0.0 c
9 ± 0.0cd
8 ± 0.0ef
6
RVE118
7 ± 0.0c
9 ± 1.0c
14 ± 0.6c
11 ± 0.0cd
12 ± 0.6ef
17 ± 0.0 f
17 ± 1.0j
5 ± 0.0b
7
RVE125
19 ± 0.0i
14 ± 0.0f
9 ± 0.6b
11 ± 0.0cd
9 ± 0.6c
21 ± 0.6g
14 ± 0.0gh
9 ± 0.0ef
8
RVE129
21 ± 0.6jk
25 ± 0.0j
20 ± 0.0h
18 ± 0.0gh
18 ± 0.0h
27 ± 0.0i
22 ± 0.0l
22 ± 0.6j
9
RVE133
0 ± 0.0a
17 ± 1.0g
20 ± 0.0h
17 ± 0.6gh
0 ± 0.0a
12 ± 1.2cd
10 ± 0.6cd
12 ± 0.6g
10
RVE144
0 ± 0.0a
10 ± 1.0cd
9 ± 0.0b
0 ± 0.0a
0 ± 0.0a
15 ± 1.0 f
16 ± 1.0h
16 ± 0.3h
11
RVE165
12 ± 0.0de
17 ± 0.6g
16 ± 0.6de
11 ± 0.0cd
14 ± 0.6fg
11 ± 0.0cd
14 ± 0.0g
10 ± 1.2g
12
RVE172
0 ± 0.0a
10 ± 0.0cd
14 ± 0.6c
0 ± 0.0a
0 ± 0.0a
19 ± 0.0g
19 ± 1.0j
5 ± 0.0b
13
RVE187
25 ± 0.6l
27 ± 0.0k
22 ± 0.0h
20 ± 1.2i
21 ± 0.0i
25 ± 1.2h
25 ± 0.6l
16 ± 0.3h
14
RVE193
22 ± 1.2k
15 ± 1.0fg
18 ± 0.0f
8 ± 0.0c
9 ± 0.6c
11 ± 0.6cd
13 ± 0.0f
9 ± 0.6ef
15
RVE194
15 ± 1.2g
13 ± 0.0f
15 ± 1.2cd
20 ± 0.6i
21 ± 0.6i
12 ± 1.0e
19 ± 1.0j
17 ± 1.2i
16
RVE214
7 ± 0.6c
11 ± 0.6de
14 ± 0.6c
7 ± 0.6b
14 ± 0.0fg
5 ± 1.0b
11 ± 1.0e
17 ± 0.6i
17
RVE217
19 ± 0.0i
25 ± 0.6j
18 ± 0.6f
22 ± 1.2j
18 ± 0.0h
26 ± 0.6i
25 ± 0.0l
16 ± 0.0h
18
RVE219
13 ± 0.0ef
8 ± 0.6c
14 ± 1.0c
8 ± 2.3c
8 ± 0.6b
7 ± 0.6b
15 ± 0.6h
18 ± 0.0i
19
RVE226
13 ± 0.6ef
8 ± 1.0c
9 ± 1.2b
0 ± 0.0a
11 ± 0.6cde
5 ± 1.0b
0 ± 0.0a
11 ± 0.3g
20
RVE227
20 ± 0.0jk
22 ± 0.0i
18 ± 0.6f
15 ± 0.0fg
18 ± 0.6h
15 ± 1.2f
10 ± 0.6cd
5 ± 0.0b
21
RVE234
14 ± 0.6g
15 ± 0.0fg
17 ± 0.6d
18 ± 0.6gh
18 ± 0.0h
21 ± 0.6g
22 ± 0.0k
10 ± 0.0fg
22
RVE239
17 ± 0.0h
16 ± 1.0g
15 ± 0.0cd
20 ± 0.0i
14 ± 0.6fg
15 ± 0f
18 ± 0.0i
9 ± 0.0ef
23
RVE247
12 ± 0.6de
14 ± 0.6f
8 ± 0.0b
10 ± 0.0c
14 ± 0.6fg
15 ± 0.6f
16 ± 1.0h
11 ± 1.2g
24
RVE248
11 ± 1.2cd
14 ± 0.0f
12 ± 0.6de
10 ± 1.2c
9 ± 0.6c
17 ± 1.2h
15 ± 0.6h
16 ± 0.0h
Control drug
28 ± 0.58m
25 ± 0.8j
24 ± 0.58i
29 ± 0.58k
28 ± 0.3j
25 ± 0.58h
25 ± 0.8l
29 ± 0.6k
Negative control
0 ± 0.0a
0 ± 0.0a
0 ± 0.0a
0 ± 0.0a
0 ± 0.0a
0 ± 0.0a
0 ± 0.0a
0 ± 0.0a
Note: Sa: Staphylococcus aureus; Se: Staphylococcus epidermidis; St1: Salmonella typhi ATCC-13311; Kp: Klebsiella pneumoniae; Ec: Escherichia coli; St2: Salmonella typhi ATCC-14028; Pa: Pseudomonas aeruginosa. Mean values sharing the same superscripts within a column are not significantly different at ; inhibition zone diameters are expressed as mean ± SD of the three replications.